Entvin AI, a cutting-edge AI solutions provider for the pharmaceutical and life sciences sectors, has officially launched out of beta and raised $500K in its maiden funding round from Y Combinator.

The fresh infusion of capital will be used to enhance its AI capabilities and accelerate customer acquisition among mid-to-large pharmaceutical companies globally, the company announced in a press release

Founded in 2022 by Sanskar Jain, Hemant Phalak, and Rishabh Arya, Entvin AI aims to streamline the complex and resource-intensive FDA drug approval process. The traditional approval process often spans several years and costs millions of dollars, making inefficiencies a significant challenge for pharmaceutical firms. Delays can impact revenue streams and postpone the availability of life-saving treatments.

To address these hurdles, Entvin has developed an AI-powered platform designed specifically for regulatory teams. Its advanced automation capabilities assist in document drafting, compliance verification, and regulatory monitoring—tasks that are historically time-consuming and error-prone.

Entvin’s proprietary platform leverages large language models fine-tuned for regulatory documentation and FDA compliance requirements. By automating repetitive tasks and identifying compliance gaps, the platform enables companies to enhance accuracy, reduce manual workloads, and navigate regulatory approvals with greater efficiency.

Early enterprise pilot users have reported significant efficiency gains, with regulatory teams reclaiming hundreds of hours previously spent on manual compliance tasks. The AI-driven system provides real-time insights and ensures seamless integration into existing regulatory workflows.

With early successes and strong backing from Y Combinator, Entvin AI is poised to scale its operations and bring its transformative solution to a broader market. As the pharmaceutical industry continues to embrace AI-driven innovation, Entvin stands at the forefront, helping life sciences companies accelerate drug approvals while maintaining compliance and trust.

By tackling one of the most critical bottlenecks in the pharmaceutical sector, Entvin AI is set to redefine how regulatory approvals are managed, ultimately contributing to faster and more efficient access to essential treatments for patients worldwide.